MRNA-Based Vaccines and Mode of Action

Overview

Journal Curr Top Microbiol Immunol

Specialties Allergy & Immunology
Microbiology

Date 2021 Feb 16

PMID 33591423

Citations 12

Authors

Janina Gergen

Benjamin Petsch

Affiliations

Soon will be listed here.

Abstract

In the past 20 years, the mRNA vaccine technology has evolved from the first proof of concept to the first licensed vaccine against emerging pandemics such as SARS-CoV-2. Two mRNA vaccines targeting SARS-CoV-2 have received emergency use authorization by US FDA, conditional marketing authorization by EMA, as well as multiple additional national regulatory authorities. The simple composition of an mRNA encoding the antigen formulated in a lipid nanoparticle enables a fast adaptation to new emerging pathogens. This can speed up vaccine development in pandemics from antigen and sequence selection to clinical trial to only a few months. mRNA vaccines are well tolerated and efficacious in animal models for multiple pathogens and will further contribute to the development of vaccines for other unaddressed diseases. Here, we give an overview of the mRNA vaccine design and factors for further optimization of this new promising technology and discuss current knowledge on the mode of action of mRNA vaccines interacting with the innate and adaptive immune system.

Citing Articles

[Platform technologies in vaccine development].

Hildt E Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2025; .

PMID: 40035793 DOI: 10.1007/s00103-025-04024-6.

A multi-epitope self-amplifying mRNA SARS-CoV-2 vaccine design using a reverse vaccinology approach.

Claudia B, Nugrahapraja H, Giri-Rachman E Res Pharm Sci. 2024; 19(5):520-548.

PMID: 39691299 PMC: 11648349. DOI: 10.4103/RPS.RPS_91_23.

mRNA vaccines as cancer therapies.

Huang S, Que H, Wang M, Wei X Chin Med J (Engl). 2024; 137(24):2979-2995.

PMID: 39668413 PMC: 11706586. DOI: 10.1097/CM9.0000000000003455.

Bioinformatics analysis to design a multi-epitope mRNA vaccine against S. agalactiae exploiting pathogenic proteins.

Barazesh M, Abbasi M, Mohammadi M, Nasiri M, Rezaei F, Mohammadi S Sci Rep. 2024; 14(1):28294.

PMID: 39550419 PMC: 11569170. DOI: 10.1038/s41598-024-79503-y.

The transformative potential of mRNA vaccines for glioblastoma and human cancer: technological advances and translation to clinical trials.

Tapescu I, Madsen P, Lowenstein P, Castro M, Bagley S, Fan Y Front Oncol. 2024; 14:1454370.

PMID: 39399167 PMC: 11466887. DOI: 10.3389/fonc.2024.1454370.

References

Allen I, Scull M, Moore C, Holl E, McElvania-TeKippe E, Taxman D . The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity. 2009; 30(4):556-65. PMC: 2803103. DOI: 10.1016/j.immuni.2009.02.005. View

Anderson B, Muramatsu H, Nallagatla S, Bevilacqua P, Sansing L, Weissman D . Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res. 2010; 38(17):5884-92. PMC: 2943593. DOI: 10.1093/nar/gkq347. View

Anderson B, Muramatsu H, Jha B, Silverman R, Weissman D, Kariko K . Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L. Nucleic Acids Res. 2011; 39(21):9329-38. PMC: 3241635. DOI: 10.1093/nar/gkr586. View

Andries O, De Filette M, De Smedt S, Demeester J, Van Poucke M, Peelman L . Innate immune response and programmed cell death following carrier-mediated delivery of unmodified mRNA to respiratory cells. J Control Release. 2013; 167(2):157-66. DOI: 10.1016/j.jconrel.2013.01.033. View

Bahl K, Senn J, Yuzhakov O, Bulychev A, Brito L, Hassett K . Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses. Mol Ther. 2017; 25(6):1316-1327. PMC: 5475249. DOI: 10.1016/j.ymthe.2017.03.035. View

Baiersdorfer M, Boros G, Muramatsu H, Mahiny A, Vlatkovic I, Sahin U . A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA. Mol Ther Nucleic Acids. 2019; 15:26-35. PMC: 6444222. DOI: 10.1016/j.omtn.2019.02.018. View

Banerjee A . 5'-terminal cap structure in eucaryotic messenger ribonucleic acids. Microbiol Rev. 1980; 44(2):175-205. PMC: 373176. DOI: 10.1128/mr.44.2.175-205.1980. View

Beddows S, Kirschner M, Campbell-Gardener L, Franti M, Dey A, Iyer S . Construction and characterization of soluble, cleaved, and stabilized trimeric Env proteins based on HIV type 1 Env subtype A. AIDS Res Hum Retroviruses. 2006; 22(6):569-79. DOI: 10.1089/aid.2006.22.569. View

Ben-Asouli Y, Banai Y, Shir A, Kaempfer R . Human interferon-gamma mRNA autoregulates its translation through a pseudoknot that activates the interferon-inducible protein kinase PKR. Cell. 2002; 108(2):221-32. DOI: 10.1016/s0092-8674(02)00616-5. View

10.

Berkovits B, Mayr C . Alternative 3' UTRs act as scaffolds to regulate membrane protein localization. Nature. 2015; 522(7556):363-7. PMC: 4697748. DOI: 10.1038/nature14321. View

11.

Bernstein P, Peltz S, Ross J . The poly(A)-poly(A)-binding protein complex is a major determinant of mRNA stability in vitro. Mol Cell Biol. 1989; 9(2):659-70. PMC: 362643. DOI: 10.1128/mcb.9.2.659-670.1989. View

12.

Beverley P . Immunology of vaccination. Br Med Bull. 2002; 62:15-28. DOI: 10.1093/bmb/62.1.15. View

13.

Beverly M, Hagen C, Slack O . Poly A tail length analysis of in vitro transcribed mRNA by LC-MS. Anal Bioanal Chem. 2018; 410(6):1667-1677. DOI: 10.1007/s00216-017-0840-6. View

14.

Borg F, Isenberg D . Syndromes and complications of interferon therapy. Curr Opin Rheumatol. 2006; 19(1):61-6. DOI: 10.1097/BOR.0b013e328010c547. View

15.

Broos K, Van der Jeught K, Puttemans J, Goyvaerts C, Heirman C, Dewitte H . Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon. Mol Ther Nucleic Acids. 2016; 5(6):e326. PMC: 5022130. DOI: 10.1038/mtna.2016.38. View

16.

Burns C, Diop O, Sutter R, Kew O . Vaccine-derived polioviruses. J Infect Dis. 2014; 210 Suppl 1:S283-93. DOI: 10.1093/infdis/jiu295. View

17.

Burton D, Hangartner L . Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. Annu Rev Immunol. 2016; 34:635-59. PMC: 6034635. DOI: 10.1146/annurev-immunol-041015-055515. View

18.

Carralot J, Probst J, Hoerr I, Scheel B, Teufel R, Jung G . Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cell Mol Life Sci. 2004; 61(18):2418-24. PMC: 7079797. DOI: 10.1007/s00018-004-4255-0. View

19.

Clarke 4th T, Clark P . Increased incidence of rare codon clusters at 5' and 3' gene termini: implications for function. BMC Genomics. 2010; 11:118. PMC: 2833160. DOI: 10.1186/1471-2164-11-118. View

20.

Crouse J, Kalinke U, Oxenius A . Regulation of antiviral T cell responses by type I interferons. Nat Rev Immunol. 2015; 15(4):231-42. DOI: 10.1038/nri3806. View